• Apaydin, E. A., Maher, A. R., Shanman, R., Booth, M. S., Miles, J. N., Sorbero, M. E., & Hempel, S. (2016). A systematic review of St. John’s wort for major depressive disorder. Systematic reviews, 5(1), 1-25.

​

• Cui, Y. H., & Zheng, Y. (2016). A meta-analysis on the efficacy and safety of St John’s wort extract in depression therapy in comparison with selective serotonin reuptake inhibitors in adults. Neuropsychiatric disease and treatment, 12, 1715.

​

• Kholghi, G., Arjmandi-Rad, S., Zarrindast, M. R., & Vaseghi, S. (2022). St. Johnʼs wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?. Naunyn-Schmiedeberg's Archives of Pharmacology, 1-14.

​

• Lawvere, S., & Mahoney, M. C. (2005). St. John's wort. American Family Physician, 72(11), 2249-2254..

​

• Linde, K., Berner, M. M., & Kriston, L. (2008). St John's wort for major depression. Cochrane database of Systematic reviews, (4).

​

• Ng, Q. X., Venkatanarayanan, N., & Ho, C. Y. X. (2017). Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis. Journal of affective disorders, 210, 211-221.

• Nobakht, S. Z., Akaberi, M., Mohammadpour, A. H., Moghadam, A. T., & Emami, S. A. (2022). Hypericum perforatum: Traditional uses, clinical trials, and drug interactions. Iranian Journal of Basic Medical Sciences, 25(9).

• Zhao, X., Zhang, H., Wu, Y., & Yu, C. (2022). The efficacy and safety of St. John’s wort extract in depression therapy compared to SSRIs in adults: A meta-analysis of randomized clinical trials. Adv. Clin. Exp. Med.

• Apaydin, E. A., Maher, A. R., Shanman, R., Booth, M. S., Miles, J. N., Sorbero, M. E., & Hempel, S. (2016). A systematic review of St. John’s wort for major depressive disorder. Systematic reviews, 5(1), 1-25.

​

• Lawvere, S., & Mahoney, M. C. (2005). St. John's wort. American Family Physician, 72(11), 2249-2254..

• Linde, K., Berner, M. M., & Kriston, L. (2008). St John's wort for major depression. Cochrane database of Systematic reviews, (4).

​

• Ng, Q. X., Venkatanarayanan, N., & Ho, C. Y. X. (2017). Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis. Journal of affective disorders, 210, 211-221.

​

• Zhao, X., Zhang, H., Wu, Y., & Yu, C. (2022). The efficacy and safety of St. John’s wort extract in depression therapy compared to SSRIs in adults: A meta-analysis of randomized clinical trials. Adv. Clin. Exp. Med.

​

• Zirak, N., Shafiee, M., Soltani, G., Mirzaei, M., & Sahebkar, A. (2019). Hypericum perforatum in the treatment of psychiatric and neurodegenerative disorders: Current evidence and potential mechanisms of action. Journal of cellular physiology, 234(6), 8496-8508.

• Kenda, M., Kočevar Glavač, N., Nagy, M., & Sollner Dolenc, M. (2022). Medicinal plants used for anxiety, depression, or stress treatment: An update. Molecules, 27(18), 6021

• Nicolussi, S., Drewe, J., Butterweck, V., & Meyer zu Schwabedissen, H. E. (2020). Clinical relevance of St. John's wort drug interactions revisited. British journal of pharmacology, 177(6), 1212-1226.

• Velingkar, V. S., Gupta, G. L., & Hegde, N. B. (2017). A current update on phytochemistry, pharmacology and herb–drug interactions of Hypericum perforatum. Phytochemistry Reviews, 16(4), 725-744..

• Chatterjee, S. S., Bhattacharya, S. K., Wonnemann, M., Singer, A., & Müller, W. E. (1998). Hyperforin as a possible antidepressant component of hypericum extracts. Life sciences, 63(6), 499-510.

​

• Gobbi, M., Dalla Valle, F., Ciapparelli, C., Diomede, L., Morazzoni, P., Verotta, L., ... & Mennini, T. (1999). Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn-Schmiedeberg's archives of pharmacology, 360(3), 262-269.

​

• Kenda, M., Kočevar Glavač, N., Nagy, M., & Sollner Dolenc, M. (2022). Medicinal plants used for anxiety, depression, or stress treatment: An update. Molecules, 27(18), 6021.

​

• Kholghi, G., Arjmandi-Rad, S., Zarrindast, M. R., & Vaseghi, S. (2022). St. Johnʼs wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?. Naunyn-Schmiedeberg's Archives of Pharmacology, 1-14.

​

• Leuner, K., Kazanski, V., Muller, M., Essin, K., Henke, B., Gollasch, M., ... & Müller, W. E. (2007). Hyperforin—a key constituent of St. John's wort specifically activates TRPC6 channels. The FASEB Journal, 21(14), 4101-4111.

• Leuner, K., Li, W., Amaral, M. D., Rudolph, S., Calfa, G., Schuwald, A. M., ... & Pozzo‐Miller, L. (2013). Hyperforin modulates dendritic spine morphology in hippocampal pyramidal neurons by activating Ca2+‐permeable TRPC6 channels. Hippocampus, 23(1), 40-52.

​

• Singer, A., Wonnemann, M., & Müller, W. E. (1999). Hyperforin, a Major Antidepressant Constituent of St. John’s Wort, Inhibits Serotonin Uptake by Elevating Free Intracellular Na+ 1 1. Journal of Pharmacology and Experimental Therapeutics, 290(3), 1363-1368.

​

• Tian, J., Zhang, F., Cheng, J., Guo, S., Liu, P., & Wang, H. (2014). Antidepressant-like activity of adhyperforin, a novel constituent of Hypericum perforatum L. Scientific Reports, 4(1), 1-6.

​

• Treiber, K., Singer, A., Henke, B., & Müller, W. E. (2005). Hyperforin activates nonselective cation channels (NSCCs). British journal of pharmacology, 145(1), 75-83.

​

• Yoshitake, T., Iizuka, R., Yoshitake, S., Weikop, P., Müller, W. E., Ögren, S. O., & Kehr, J. (2004). Hypericum perforatum L (St John's wort) preferentially increases extracellular dopamine levels in the rat prefrontal cortex. British journal of pharmacology, 142(3), 414-418.

​

• Zirak, N., Shafiee, M., Soltani, G., Mirzaei, M., & Sahebkar, A. (2019). Hypericum perforatum in the treatment of psychiatric and neurodegenerative disorders: Current evidence and potential mechanisms of action. Journal of cellular physiology, 234(6), 8496-8508.

• Jakobs, D., Hage-Hülsmann, A., Prenner, L., Kolb, C., Weiser, D., & Häberlein, H. (2013). Downregulation of β1-adrenergic receptors in rat C6 glioblastoma cells by hyperforin and hyperoside from St John's wort. Journal of Pharmacy and Pharmacology, 65(6), 907-915.

• Kenda, M., Kočevar Glavač, N., Nagy, M., & Sollner Dolenc, M. (2022). Medicinal plants used for anxiety, depression, or stress treatment: An update. Molecules, 27(18), 6021.

​

• Moragrega, I., & Ríos, J. L. (2021). Medicinal plants in the treatment of depression: Evidence from preclinical studies. Planta medica, 87(09), 656-685.

​

• Müller, W. E., Rolli, M., Schäfer, C., & Hafner, U. (1997). Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry, 30(S 2), 102-107.

​

• Prenner, L., Sieben, A., Zeller, K., Weiser, D., & Häberlein, H. (2007). Reduction of high-affinity β2-adrenergic receptor binding by hyperforin and hyperoside on rat C6 glioblastoma cells measured by fluorescence correlation spectroscopy. Biochemistry, 46(17), 5106-5113.

• Simbrey, K., Winterhoff, H., & Butterweck, V. (2004). Extracts of St. John's wort and various constituents affect β-adrenergic binding in rat frontal cortex. Life sciences, 74(8), 1027-1038.

• Kholghi, G., Arjmandi-Rad, S., Zarrindast, M. R., & Vaseghi, S. (2022). St. Johnʼs wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?. Naunyn-Schmiedeberg's Archives of Pharmacology, 1-14.

​

• Müller, W. E. (2003). Current St. John’s wort research from mode of action to clinical efficacy. Pharmacological research, 47(2), 101-109.

​

• Müller, W. E., Singer, A., Wonnemann, M., Hafner, U., Rolli, M., & Schäfer, C. (1998). Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry, 31(S 1), 16-21.

• Yoshitake, T., Iizuka, R., Yoshitake, S., Weikop, P., Müller, W. E., Ögren, S. O., & Kehr, J. (2004). Hypericum perforatum L (St John's wort) preferentially increases extracellular dopamine levels in the rat prefrontal cortex. British journal of pharmacology, 142(3), 414-418.

• Gobbi, M., Dalla Valle, F., Ciapparelli, C., Diomede, L., Morazzoni, P., Verotta, L., ... & Mennini, T. (1999). Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn-Schmiedeberg's archives of pharmacology, 360(3), 262-269.

​

• Kholghi, G., Arjmandi-Rad, S., Zarrindast, M. R., & Vaseghi, S. (2022). St. Johnʼs wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?. Naunyn-Schmiedeberg's Archives of Pharmacology, 1-14.

​

• Müller, W. E., Rolli, M., Schäfer, C., & Hafner, U. (1997). Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry, 30(S 2), 102-107.

• Yoshitake, T., Iizuka, R., Yoshitake, S., Weikop, P., Müller, W. E., Ögren, S. O., & Kehr, J. (2004). Hypericum perforatum L (St John's wort) preferentially increases extracellular dopamine levels in the rat prefrontal cortex. British journal of pharmacology, 142(3), 414-418.

​

• Zirak, N., Shafiee, M., Soltani, G., Mirzaei, M., & Sahebkar, A. (2019). Hypericum perforatum in the treatment of psychiatric and neurodegenerative disorders: Current evidence and potential mechanisms of action. Journal of cellular physiology, 234(6), 8496-8508.

• Kholghi, G., Arjmandi-Rad, S., Zarrindast, M. R., & Vaseghi, S. (2022). St. Johnʼs wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?. Naunyn-Schmiedeberg's Archives of Pharmacology, 1-14.

​

• Moragrega, I., & Ríos, J. L. (2021). Medicinal plants in the treatment of depression: Evidence from preclinical studies. Planta medica, 87(09), 656-685.

​

• Volz, H. P. (2020). Hypericum and Depression. NeuroPsychopharmacotherapy, 1-8.

• Franklin, M., Reed, A., & Murck, H. (2004). Sub-chronic treatment with an extract of Hypericum perforatum (St John’s wort) significantly reduces cortisol and corticosterone in the rat brain. European Neuropsychopharmacology, 14(1), 7-10.

​

• Grundmann, O. L. V. Y., Lv, Y., Kelber, O., & Butterweck, V. (2010). Mechanism of St. John's wort extract (STW3-VI) during chronic restraint stress is mediated by the interrelationship of the immune, oxidative defense, and neuroendocrine system. Neuropharmacology, 58(4-5), 767-773.

• Velingkar, V. S., Gupta, G. L., & Hegde, N. B. (2017). A current update on phytochemistry, pharmacology and herb–drug interactions of Hypericum perforatum. Phytochemistry Reviews, 16(4), 725-744.

• Velingkar, V. S., Gupta, G. L., & Hegde, N. B. (2017). A current update on phytochemistry, pharmacology and herb–drug interactions of Hypericum perforatum. Phytochemistry Reviews, 16(4), 725-744.